For more information on Alvine Phase 2a study of ALV003, please visitAbout Celiac Diseaseceliac disease the most common hereditary with an with an estimated prevalence Complications 1-2 percent in the U ventolin prospect more info .S. And EU Intestinal inflammation in celiac disease the ingestion of gluten the ingestion of gluten in genetically susceptible people. Gluten is a protein wheat wheat, rye and barley, and is one of the most common and nutritionally significant part of human nutrition. Patients with celiac disease, an immune response to gluten and gluten fragments, resulting in systemic immune-mediated damage in the gut and other organs. Gluten ingestion can be associated with symptoms such as nausea, diarrhea, constipation and rash. Complications of celiac disease include osteoporosis, anemia, dermatitis, weight loss, diabetes, central nervous system conditions including depression, autoimmune diseases and tumors. The only option available for people diagnosed with celiac disease today is a life of a strict gluten-free diet, which is very difficult to follow.
Was designediates Enrollment In Phase 2a trial of ALV003 for use in the treatment of celiacAlvine Pharmaceuticals, announced that patient enrollment commenced in a Phase 2a, assessing randomized, double – blind, placebo – controlled study the safety and efficacy of ALV003 for use in the treatment of celiac disease. – The initiation of this Phase 2a milestone in the clinical milestone in the clinical development of ALV003 as a potential therapeutic option for patients with celiac disease, said Daniel C. Adelman, Alvine ‘s Senior Vice President of Development and Chief Medical Officer. Continue reading